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Abstract  36 
 37 
Remarkable progress in molecular analyses has improved our understanding of the 38 
evolution of cancer cells towards immune escape1–5. However, the spatial configurations of 39 
immune and stromal cells, which may shed light on the evolution of immune escape across 40 
tumor geographical locations, remain unaddressed. We integrated multi-region exome and 41 
RNA-seq data with spatial histology mapped by deep learning in 100 non-small cell lung 42 
cancer (NSCLC) patients from the TRAcking Cancer Evolution through Therapy (Rx) 43 
(TRACERx) cohort6. Cancer subclones derived from immune cold regions were more closely 44 
related in mutation space, diversifying more recently than subclones from immune hot 45 
regions. In TRACERx and in an independent multi-sample cohort of 970 lung 46 
adenocarcinoma (LUAD) patients, the number of immune cold regions significantly 47 
correlated with risk of relapse, independently of tumor size, stage and number of samples 48 
per patient. In LUAD, but not lung squamous cell carcinoma (LUSC), geometrical irregularity 49 
and complexity of the cancer-stromal cell interface significantly increased in tumor regions 50 
without disruption of antigen presentation. Decreased lymphocyte accumulation in adjacent 51 
stroma was observed in tumors with low clonal neoantigen burden. Collectively, immune 52 
geospatial variability elucidates tumor ecological constraints that may shape the emergence 53 
of immune evading subclones and aggressive clinical phenotypes.   54 
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Main Text 55 
 56 
Using an artificial intelligence framework, we developed a generalizable deep learning 57 
pipeline to spatially profile immune infiltration and discover tumor topological determinants 58 
of immunosuppression in digital pathology. Convolutional neural networks were tailored for 59 
the analysis of NSCLC morphology using diverse histology samples in the multi-region 60 
TRACERx 100 cohort6 to avoid overfitting (Methods). This approach enabled the spatial 61 
mapping of cancer cells, lymphocytes, stromal cells (fibroblasts and endothelial cells), and 62 
an “other” cell class (macrophages, pneumocytes and non-identifiable cells) in hematoxylin 63 
& eosin (H&E)-stained images (275 tumor regions from 85 patients and 100 diagnostic slides 64 
from all patients, Fig. 1a-c, CONSORT diagram Extended Data Fig. 1a-b, Supplementary 65 
Table 1). T cell subsets were also identified in CD4/CD8/FOXP3 immunohistochemistry (IHC) 66 
images for all 100 diagnostic samples (Fig. 1d).  67 
 68 
This pipeline for H&E analysis exhibited high accuracy and consistency compared with five 69 
orthogonal data types within TRACERx, including DNA-seq, RNA-seq, IHC, 5,951 single-cell 70 
annotations by pathologists (balanced accuracy, as an average of specificity and sensitivity = 71 
0.932), and pathology tumor-infiltrating lymphocyte (TIL) estimates following the guidelines 72 
developed by the International Immuno-Oncology Biomarker Working Group7 (Extended 73 
Data Fig. 2, Supplementary Table 2). The Leicester Archival Thoracic Tumor Investigatory 74 
Cohort8 (LATTICe-A, Extended Data Fig. 1c-d), a retrospective study of 970 resected LUAD 75 
patients that included H&E sections from all diagnostic tumor blocks with a median of four 76 
samples per tumor, was used for independent validation. The pipeline’s generalizability was 77 
supported using 5,082 pathologists’ single-cell annotations (balanced accuracy = 0.913), and 78 
virtual integration of IHC and H&E images generated from the same slides (Fig. 1e-h, 79 
Extended Data Fig. 2e-g, Supplementary Table 3). Using this unbiased scalable approach, 80 
immune infiltration was quantified as the percentage of all cells that were lymphocytes in 81 
each H&E image.  82 
 83 
High geospatial immune variability between tumor regions within the same patients was 84 
revealed (Fig. 2a-b), which did not reflect associations with pathological stage (Extended 85 
Data Fig. 3). To differentiate highly from poorly immune infiltrated tumor regions, regions 86 
containing a lymphocyte percentage greater than a quarter standard deviation above the 87 
median lymphocyte percentage were classified as immune hot, and regions containing a 88 
lymphocyte percentage below a quarter standard deviation of the median were classified as 89 
immune cold. The remaining 20% were classified as intermediate (Fig. 2b). Subsequent 90 
results were tested on four more classification schemes based on the standard deviation to 91 
ensure that results derived from this classification were not contingent upon choice of 92 
thresholds used (Extended Data Fig. 4). Significant difference in pathology TIL estimates was 93 
observed between immune hot and cold regions (	 = 4.6x10-8, Extended Data Fig. 5a). 94 
Significantly higher levels of RNA-seq estimated immune infiltrate1, particularly for immune 95 
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activation subsets, were consistently observed in immune hot compared to cold regions, 96 
supporting the validity of histology-based immune classification (Fig. 2c-d). We next directly 97 
compared our immune hot and cold regional classification (excluding intermediate regions) 98 
against RNA-seq-based1 classifications (  = 109 regions with histology and RNA-seq data). 78 99 
out of 109 regions were in agreement (Fisher’s exact test for overlap: 	 = 7.8x10-6, 100 
Extended Data Fig. 5b). Regions with discrepant classification (  = 31) had significantly 101 
higher spatial heterogeneity of lymphocyte distribution compared to regions concordant 102 
between the two methods (	 = 0.01, Extended Data Fig. 5c), suggesting spatial intratumor 103 
heterogeneity could contribute towards the discrepancy, since the different data types were 104 
derived from adjacent sections of the same tumor blocks. 105 
 106 
Ecological selection pressures drive genetic divergence9,10. To determine if cancer genetic 107 
divergence differs according to immune context, we calculated the genomic distance as the 108 
Euclidean distance of subclonal mutations for each pair of tumor regions with the same 109 
immune phenotype in a patient. We observed significantly lower genomic distance, 110 
indicating more shared subclonal mutations, for pairs of immune cold regions than for pairs 111 
of immune hot regions in LUAD (Fig. 3a, Extended Data Fig. 4b, 	 < 0.005 for all immune 112 
classification schemes), but not in LUSC (Extended Data Fig. 6a). In LUAD but not LUSC, 113 
analysis of immune phenotypes mapped onto the phylogenetic trees6 revealed that 114 
dominant clones (cancer cell fraction ≥ 75%, see Methods) in pairs of cold regions were 115 
more closely related on the phylogenetic tree, compared to dominant clones in pairs of 116 
immune hot regions (Fig. 3b). Moreover, dominant clones in hot regions almost always 117 
diversified at the most recent common ancestor of the tree (13/15, 87%, Fig. 3c), in contrast 118 
no such preference was observed in immune cold regions (11/23, 48%).  119 
 120 
We investigated the impact of immune context on disease-free survival. Tumors with high 121 
number of immune cold regions were at significantly increased risk of relapse that was 122 
independent of the total number of regions sampled, tumor size and stage in both histology 123 
types in TRACERx (Fig. 3d-e, Extended Data Fig. 6c-h). This association with disease-free 124 
survival was also significant using the number of immune low regions as estimated by RNA-125 
seq1 in 64 TRACERx tumors with available RNA-seq data (	 = 0.002, Extended Data Fig. 6b). 126 
Following the genomic findings in LUAD, we sought to validate this in 970 LUAD patients in 127 
the multi-sample LATTICe-A cohort, confirming the prognostic value of immune cold sample 128 
count, that was also independent of the number of samples per patient, tumor size and 129 
stage (Fig. 3f-g, Extended Data Fig. 6c-e). In both cohorts, the number of immune cold 130 
samples per patient correlated with relapse, more significantly than any other immune 131 
feature generated using deep learning, including the average and variability of lymphocyte 132 
percentage per tumor, number of immune hot regions, proportion of immune cold regions 133 
to the number of regions sampled, as well as CD8+ cell percentage or CD8+ to CD4+FOXP3+ 134 
ratio in TRACERx diagnostic slides (Extended Data Fig. 6e).  135 
 136 
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Studies have revealed immunosuppressive fibroblast subsets localizing to the boundary of 137 
tumor nests possibly contribute to T cell exclusion11–13. Therefore, we hypothesized that 138 
increased cancer-stroma physical contact may reflect stroma-modulated inhibition of anti-139 
tumor immune responses14–17.  To measure the physical contact between cancer and 140 
stromal cells (the majority being fibroblasts) identified by image analysis, we developed a 141 
spatial measure, using fractal dimension to quantify the geographical irregularity and 142 
complexity of the cancer-stromal cell interface (Methods, Fig. 4a, Extended Data Fig. 7a,b,e). 143 
Within the same tissue space, higher fractal dimension of cancer-stromal cell interface 144 
suggests increased geometric irregularity and more extensive physical contact between 145 
tumor and stromal cells than samples with a smooth interface. For both histology types, 146 
fractal dimension was significantly higher in immune cold regions compared to immune hot 147 
regions (Fig. 4b, Extended Data Fig. 7c). Moreover, the difference in fractal dimension 148 
between immune cold and hot regions was more significant compared to the difference in 149 
stromal cell percentage (both histology types combined: 	 = 0.00036, effect size 0.49 for 150 
fractal dimension versus 	 = 0.018, effect size 0.38 for stromal cell percentage, Extended 151 
Data Fig. 7d), suggesting the importance of stromal cell geographical location rather than 152 
their quantity. This supports the hypothesis that the stroma-based inhibition of immune 153 
infiltration17 may result from a specific topological pattern in the form of cancer-stroma 154 
engagement.  155 
 156 
To understand the associations of stromal-mediated immunosuppression in the context of 157 
the genetic mechanisms of immune evasion, we related fractal dimension to dysfunction in 158 
antigen presentation through loss of heterozygosity at the human leukocyte antigen locus 159 
(HLA LOH), which has been identified as a potent immune escape mechanism1,18. A 160 
significantly higher fractal dimension was found in LUAD tumor regions with intact HLA 161 
alleles compared with regions harboring HLA LOH (Fig. 4c, Extended Data Fig. 7f). This was 162 
observed at the tumor level (see Methods for definition), independent of clonal neoantigen 163 
burden (	 = 0.04, multivariate regression, Extended Data Fig. 7h), but was not observed in 164 
LUSC (Extended Data Fig. 7g, i).  165 
 166 
Although clonal neoantigens have been associated with a cytotoxic immune response19, the 167 
spatial distribution of lymphocytes in relation to clonal neoantigens remained unclear. To 168 
provide sufficient spatial context for analysis of cell distribution, whole-section TRACERx 169 
diagnostic H&E images, typically 10x larger than the regional samples, were used. To test 170 
the relationship between lymphocyte spatial distribution and clonal neoantigens, we 171 
leveraged an established method for lymphocyte spatial modeling20. Each lymphocyte was 172 
classified into three distinct spatial compartments: intra-tumor, adjacent-to-tumor or distal-173 
tumor, based on unsupervised modeling of cancer-lymphocyte proximity (Fig. 4d). In LUAD, 174 
but not LUSC, clonal neoantigens19 were found to be associated with a specific immune 175 
spatial score to approximate pathology TIL estimates7, defined as the ratio of adjacent-176 
tumor lymphocytes to stromal cells in the diagnostic H&E samples (	 = 0.0074, high clonal 177 
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neoantigen defined as above median in LUAD, Fig. 4e; correlation as continuous variables 178 
Rho = 0.37, 	 = 0.035 after multiple testing correction, Extended Data Fig. 8a). By contrast, 179 
subclonal neoantigen burden did not correlate with any immune score (Extended Data Fig. 180 
8a), supporting the notion that clonal but not subclonal neoantigens is associated with 181 
infiltration of cytotoxic T cells19 adjacent to tumor nests. 182 
 183 
To determine if there was an enrichment of a specific lymphocyte subpopulation within the 184 
adjacent-tumor compartment in LUAD, we spatially aligned IHC to H&E in 10 samples with 185 
the highest adjacent-tumor lymphocytes to stromal cell ratio, and projected IHC-derived T 186 
cell subsets onto H&E images, thereby creating virtual staining of cells in the H&E sections 187 
(Methods, Fig. 4f, Extended Data Fig. 8b-c). CD4+FOXP3-, CD8+, and CD4+FOXP3+ cells 188 
classified in IHC were projected onto a density map of cancer cell distribution inferred from 189 
H&E, and were classified into adjacent-tumor, intra-tumor, and distal-tumor compartments. 190 
In this limited dataset, a significant increase of the effector-regulator balance defined by 191 
CD8+/CD4+FOXP3+ cell ratio was observed in adjacent-tumor stroma compared to the distal 192 
tumor compartment (Fig. 4g). 193 
 194 
In summary, by training deep learning algorithms in diverse histology samples, we 195 
demonstrated that digital pathology can provide accurate tools for defining the ecological 196 
spatial context that may improve our understanding of cancer evolution and the immune 197 
response. In TRACERx and LATTICe-A cohorts, LUAD tumors with increased immune cold 198 
regions were at a significantly higher risk of cancer relapse, independent of total regions 199 
sampled and immune phenotypes of other regions. Thus, even within a tumor that has on 200 
average increased immune infiltration, if it contains regions classified as immune cold, 201 
prognosis appears to be associated with the number of cold regions. Analysis of cancer 202 
branched evolution within the ecological context of immune hot and cold regions revealed a 203 
difference in the evolution history of cancer subclones in these regions, possibly as a result 204 
of immunoediting. Based on this finding, we speculate that by identifying the subclone 205 
where immunoediting is likely to have occurred, new drivers of immune evasion may be 206 
elucidated. 207 
 208 
Spatial histology data can extend our knowledge of the tumor microenvironment 209 
topological configuration in relation to genetic alterations relevant to immune surveillance, 210 
including HLA LOH and clonal neoantigens in LUAD (Extended Data Fig. 9). Increased cancer-211 
stromal engagement as measured by fractal dimension may signal physical constraints 212 
against T cell ingress. This is supported by previous studies in lung cancer showing 213 
restriction of CD8+ and CD4+ T cell motility in dense stromal extracellular matrix areas 214 
around tumor epithelial cell regions which prevent them from entering tumor islets13. 215 
Additionally, the association between specific spatial localization of lymphocytes in tumor-216 
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adjacent stroma and clonal neoantigens further support exploration of the role of stromal 217 
cells in limiting tumor infiltration by T cells14–17.  218 
 219 
It will be imperative to validate our findings on a larger multi-region cohort of untreated 220 
NSCLC tumors. Differences in our findings pertaining to LUAD and LUSC may reflect 221 
differences in biology21–23 and immune evasion mechanisms, including increased prevalence 222 
of antigen presentation dysfunction (HLA transcriptional repression and HLA LOH1) in LUSC. 223 
Other limitations include the lack of detailed staining using multiplexing technologies24–26 224 
that could provide further insights into immune composition. However, with advanced deep 225 
learning developments and detailed tumor phylogenetic data, histology can be used to 226 
highlight fundamental immune contexture such as immune exclusion and its topological 227 
determinants. These data illuminate the clinical significance of immune cold regions that 228 
may reflect immune evading subclones, warranting further investigation into mechanisms 229 
that could contribute to the spatial variability of immune cells. 230 
  231 
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Figures legends 232 
 233 
Figure 1. The computational pathology deep learning pipeline for dissecting 234 
heterogeneous NSCLC tumor microenvironment. a. Histology sample generation in Lung 235 
TRACERx. To preserve morphology and generate good quality histology, samples from the 236 
same tumor regional frozen blocks specifically collected for TRACERx and generated 237 
molecular data1,6 were re-embedded in formalin fixed paraffin (FFPE). From these, H&E-238 
stained tumor section slides were generated. In addition, H&E section and triplex 239 
CD4/CD8/FOXP3 IHC slides were also generated from diagnostic blocks that represent 240 
clinical standard sampling. b. Our multistage deep learning pipeline consists of three key 241 
stages: fully automated tissue segmentation, single-cell detection and classification. The 242 
final output is shown as an image with all cells identified. For more details, please see the 243 
‘Training the deep learning pipeline’ section of the Methods. c. Illustrative 3-dimensional 244 
distribution of input image patches in the feature space learned by the convolutional neural 245 
networks, using Principal Component Analysis. The feature clusters were pseudo-colored to 246 
display segregation for four cell types in H&E, and d CD8+, CD4+FOXP3+, CD4+FOXP3- and 247 
“other” cell class (hematoxylin cells) in IHC, respectively. e. The deep learning single-cell 248 
classification model was trained using expert pathology annotations from a variety of 249 
TRACERx samples (diagnostic, regional, TMA). The trained model was then applied to the 250 
remaining TRACERx samples (predominantly LUAD and LUSC) and the LATTICe-A cohort 251 
(only LUAD), identifying over 171 million cells in TRACERx and over 4.9 billion cells in 252 
LATTICe-A. WSI: whole-section image. f. Biological validation of the deep learning approach. 253 
H&E and IHC images generated from the same TMA slide were virtually integrated for 254 
comparison of H&E-based cell classification and cell type marker expression. For each 255 
marker, the experiment was conducted once using a single TMA (  cores/patients = 48 256 
TTF1; 38 CD45). Scale bars represent 100µm. g-h. Correlations between cancer/lymphocyte 257 
cell percentage determined by H&E and TTF1+ (tumor marker)/CD45+ (immune marker) cell 258 
percentage per LUAD image tiles of size 100µm2 ( 	= 100 TTF1; 83 CD45). The shading 259 
indicates 95% confidence interval.  260 
 261 
Figure 2. Geospatial heterogeneity of lymphocytic infiltration in the TRACERx cohort. a. 262 
Representative examples of immune hot and immune cold multi-region H&E samples, scale 263 
bars represent 100µm. b. Each column represents a tumor, grouped by their histologic 264 
subtype (the “Other” group consists of adenosquamous carcinoma, large cell 265 
neuroendocrine carcinoma, pleomorphic carcinoma, and sarcomatoid carcinoma of 266 
pleomorphic type arising from adenocarcinoma). Tumor regions (illustrated as dots) were 267 
assigned to immune hot, immune cold, and intermediate phenotypes based on percentage 268 
of lymphocytes in all cells following H&E-based deep learning analysis. CD8+/CD4+FOXP3-269 
/CD4+FOXP3+ percentages based on automated analysis of the IHC diagnostic samples are 270 
also shown. c. A heatmap showing gene expression patterns of 14 immune cell populations 271 
across tumor regions, each row represents a tumor region (  = 142). The three clusters 272 
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correspond to the proposed immune regional classification as shown in b. d. Significant 273 
enrichment of all immune cell populations in hot regions, as compared to cold regions, 274 
particularly for the immune activating cell subsets, including cytotoxic, B-cell, and natural 275 
killer cells (  = 109 regions; 52 patients). A two-sided, non-parametric, unpaired, Wilcoxon 276 
signed-rank test was used for each box plot, all -values were corrected for multiple 277 
comparisons. Thick horizontal lines indicate the median value; outliers are indicated by the 278 
extreme points; the first and third quantiles are represented by the box edges; and vertical 279 
lines indicate the error range.  280 
 281 
Figure 3. Evolution of immune escape, and survival analysis in TRACERx and LATTICe-A. a. 282 
A box plot showing the difference in genomic distances for pairs of immune hot or immune 283 
cold regions within the same patients in LUAD (  = 66 pairs). b. A box plot showing the 284 
difference in mutational distance between the dominant subclones in pairs of immune hot 285 
or immune cold regions via their last common ancestor in LUAD (  = 23 immune cold pairs; 286 
15 immune hot pairs). This distance was calculated by taking the furthest dominant clone 287 
(cancer cell fraction (CCF) ≥ 75%) from the trunk, and it remained significant when the 288 
dominant clone closest to the most recent common ancestor of each tree was considered 289 
(	 = 0.02). c. Illustrative examples of tumor phylogenetic trees for a pair of immune hot and 290 
immune cold regions. Dominant subclones were labelled and their last common ancestor 291 
(annotated with arrows) was then identified. Minor (CCF < 75%) or undetected clones were 292 
neglected in this analysis. d,e. Kaplan-Meier curves illustrating the difference in disease-free 293 
survival according to the number of immune cold regions, dichotomized by the median 294 
value, in TRACERx (d) (LUAD and LUSC,  = 79 patients, 249 regions) and LATTICe-A (e) 295 
(LUAD,  = 970 patients, 4,324 samples). The same deep learning histology analysis and 296 
immune regional classification developed for TRACERx were applied directly to LATTICe-A. 297 
WSI: whole-section image. f. Forest plots showing multivariate Cox regression analyses in 298 
TRACERx (  = 79 patients; LUAD and LUSC). Clonal neoantigens were dichotomized using the 299 
upper quartile, determined individually for LUAD and LUSC tumors1. g. Forest plots showing 300 
multivariate Cox regression analyses in LATTICe-A (  = 651 LUAD patients with complete 301 
stage and smoking pack years data). For the patient subset with complete stage data but 302 
missing pack years information, the test remained significant (  = 827, 	 < 0.001, HR = 303 
1.4[1.1-1.9]). For statistical comparisons among groups, a two-sided, non-parametric, 304 
unpaired, Wilcoxon signed-rank test was used, unless stated otherwise. 305 
 306 
Figure 4. Association of spatial histology with genetic alterations relevant to immune 307 
surveillance. a. An illustrative example of fractal dimension calculated by the box-counting 308 
algorithm to quantify the geospatial complexity of the cancer cell-stromal cell interface. By 309 
examining boxes of decreasing sizes that contain both cancer and stromal cells, the box 310 
counting algorithm quantifies the rate at which the geometrical details of cancer-stromal 311 
interface develop at increasingly fine scales. Blue box illustrates the smallest box of 20μm by 312 
20μm in size. Scale bar represent 100µm. An example of a fractal structure displaying 313 
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geometrical self-similarity is shown below the panel. b. A box plot to illustrate the significant 314 
difference in fractal dimension between all TRACERx immune hot and cold regions (  = 219). 315 
c. A box plot showing a significant difference in fractal dimension between LUAD tumor 316 
regions (  = 116) harboring an LOH event for class 1 HLA of any type versus regions that do 317 
not, adjusted for multiple comparisons with the remaining HLA type-specific tests (see 318 
Extended Data Fig. 7f). d. Illustration of the adjacent-tumor lymphocyte/stroma ratio 319 
inferred by spatial modeling of cancer cell density (contours) and lymphocyte classification 320 
into spatial compartments. Cell classification in IHC sample of the same block was shown for 321 
comparison. Scale bars represent 50μm. e. A box plot showing the difference in the 322 
adjacent-tumor lymphocyte/stroma ratio between high (≥ median) and low (< median) 323 
clonal neoantigens for all LUAD patients in TRACERx (  = 61). f. Illustration of image 324 
registration to spatially align serial sections of H&E and IHC and generate a virtual composite 325 
map of T cell subset in the context of cancer/stroma density. T cell subsets classified in the 326 
IHC were projected onto the cancer density map inferred from H&E, so that they can be 327 
classified into adjacent-tumor, intra-tumor, and distal-tumor compartments. g. A box plot 328 
showing significantly higher ratio of CD8+ to CD4+FOXP3+ cells in adjacent-tumor and intra-329 
tumor lymphocytes compared with distal-tumor lymphocytes in registered LUAD image tiles 330 
(  = 20 image tiles, using paired Wilcoxon test). For statistical comparisons among groups, a 331 
two-sided, non-parametric, unpaired, Wilcoxon signed-rank test was used, unless stated 332 
otherwise. 333 
 334 
  335 
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Tissues and digital images 490 
The main cohort evaluated comes from the first 100 patients prospectively analyzed by the 491 
lung TRACERx study6 (Extended Data Fig. 1, Supplementary Tables 1, 4, 492 
https://clinicaltrials.gov/ct2/show/NCT01888601, approved by an independent Research 493 
Ethics Committee, 13/LO/1546). 62 were men and 38 were women, with a median age of 494 
68. 61 were LUAD, 32 were LUSC and the remaining 7 had ‘other’ histology subtypes 495 
(including adenosquamous carcinoma, large cell carcinoma, large cell neuroendocrine 496 
carcinoma, pleomorphic carcinoma and pleomorphic carcinoma arising from 497 
adenocarcinoma).  498 
 499 
The 85 case subcohort with regional histology consisted of 55 male and 30 female patients 500 
and of those 49 were LUAD, 32 were LUSC and 6 were ‘other’ types. 10 of these patients 501 
had a single region while the rest ranged between 2-8 regions (  = 275 total regional 502 
histology samples). Snap-frozen regional samples were processed to FFPE blocks after 503 
dissecting fresh-frozen tissues for DNA-seq and RNA-seq analyses. Tissue microarrays (TMAs) 504 
were created containing 133x2mm regional tissue cores from 75 patients in 7 blocks. 505 
 506 
In addition to the regional samples, full-sized diagnostic blocks were obtained for all 100 507 
cases precisely mirroring the Jamal-Hanjani et al. 2017 prospective 100 patient cohort6.  508 
4µm thick sections were cut and subjected to H&E staining and multiplex IHC for 509 
CD8/CD4/FOXP3: anti-CD8 (type: Rabbit Monoclonal, clone: SP239, cat. no.: ab178089, 510 
source: Abcam Plc, Cambridge, UK, used at 1:100); anti-CD4 (type: Rabbit Monoclonal, 511 
clone: SP35, cat. no.: ab213215, source: Abcam Plc, Cambridge, UK, used at 1:50); anti-512 
FOXP3 (type: Mouse, clone: 236A/E7, source: kind gift from Dr G Roncador, CNIO, Madrid, 513 
Spain, used at: 1:100). All regional and diagnostic slides were scanned using NanoZoomer 514 
S210 digital slide scanner (C13239-01) and NanoZoomer digital pathology system version 515 
3.1.7 (Hamamatsu, Japan) at 40x (228 nm/pixel resolution).   516 
 517 
The external validation cohort was obtained from the Leicester Archival Thoracic Tumor 518 
Investigatory Cohort – Adenocarcinoma (LATTICe-A) study8, a continuous retrospective 519 
series of resected primary LUAD tumors from a single surgical center between years 1998 to 520 
2014 (Extended Data Fig. 1, Supplementary Table 5). It consists of 4,324 whole-tumor 521 
diagnostic blocks from 970 LUAD patients (ranging from 1 to 16 blocks per case with a 522 
median of 4). 455 were men and 515 were women with a median age of 69. Most clinical 523 
data (age, sex, adjuvant therapy status and time to recurrence or death) were available for 524 
all patients, with complete pathological stage for 827 and smoking history for 651. All 525 
archival slides containing tumor material were used in order to capture the full diversity of 526 
each lesion. Slides were dearchived and scanned using a Hamamatsu NanoZoomer XR at 40x 527 
(226 nm/pixel resolution) yielding 15 TB of image data. Images containing incidental lymph 528 
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node tissue were excluded to avoid confounding immune infiltration analysis. For the 529 
biological validation assay, a subset of 49 paraffin blocks from 49 patients was obtained 530 
from the same study, and from these a validation TMA was prepared, containing a single 531 
1mm core from each case. The work was ethically approved by an NHS research ethics 532 
committee (ref. 14/EM/1159). This study complies with the STROBE guidelines. 533 
 534 
The deep learning pipeline for cell detection and classification  535 
The deep learning pipeline consists of three parts. First, the pipeline segments tissue regions 536 
utilizing multi-resolution input/output image features (Micro-Net27). It was designed to 537 
capture global tissue context and learn weak features that could be important for 538 
identifying tissue boundary, but are often not achieved by other machine learning methods 539 
such as thresholding of the grey-scale image, active contours, watershed segmentation or 540 
Support Vector Machine-based training on local binary pattern features27. Tissue 541 
segmentation removes background noise and artefacts and subsequently allows for more 542 
computationally efficient cell detection and accurate classification. Secondly, a cell 543 
detection model modified from SCCNN28 predicts for each pixel the probability that it 544 
belongs to the center of a nucleus within tissue regions identified by Micro-Net. Nuclei are 545 
detected from the probability map obtained from the deep network. Lastly, a cell 546 
classification framework utilizes a neighboring ensemble predictor classifier coupled with 547 
SCCNN to classify each cell by type.  548 
 549 
For tissue segmentation, each whole slide image was reduced to 1.25x resolution and 550 
segmented for tissue regions using Micro-Net-51227 architecture. This architecture visualizes 551 
the image at multiple resolutions, captures context information by connecting intermediate 552 
deep layers and adds bypass connections to max-pooling to maintain weak features (Fig. 553 
1b). 10 whole slide images were used to train the tissue segmentation network using Micro-554 
Net. The segmented images from the network were inspected visually and quantitatively 555 
(Supplementary Table 6, Supplementary Figures 1-20) to evaluate performance using an 556 
independent set of images. 557 
 558 
The SCCNN adds two layers to conventional deep learning architecture for cell detection 559 
within the segmented tissue. SC1 estimates the location and probability of each pixel 560 
belonging to the center of a cell, and these probabilities are then mapped by SC2 to the 561 
image. A customized implementation of SCCNN was coded in Python (version 3.5) using 562 
TensorFlow29 library (version 1.3) which makes it computationally more efficient compared 563 
to the original MATLAB implementation28. To process an image of size 1000×1000 pixels, the 564 
Python implementation takes 4.8 seconds for nucleus detection compared to 41.0 seconds 565 
using the original implementation28, excluding preprocessing which remained the same in 566 
both implementations (using MATLAB (version 2018b)). In addition, through empirical 567 
experimentation, we optimized the patch size to 31x31 instead of 27x27 in the original 568 
implementation for increased cell detection accuracy. To generate nuclear locations from 569 
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the SC2 probability map, peak detection was applied where thresholds for intensity and 570 
minimum grouping distance were also optimized to 0.15 and 12 pixels through 571 
experimentation using validation data. 572 
 573 
For cell classification, a neighboring ensemble predictor was used. This predictor utilizes 574 
SCCNN to classify cells in neighboring locations to the detected center of the cell. In our 575 
implementation, the ensemble classifier required votes from SCCNN classification of nine 576 
different neighborhood locations near to the center of the cell compared to five votes in 577 
original implementation. Through experimentation, the patch size was optimized to 51x51 578 
for classification instead of 27x27 as originally proposed. This permitted incorporation of 579 
greater tissue spatial context while maintaining the accuracy of classifying small cells.  580 
 581 
Altogether, this pipeline enabled the spatial mapping of four cell types from H&E images: 582 
cancer (malignant epithelial) cells, lymphocytes (including plasma cells), non-inflammatory 583 
stromal cells (fibroblasts and endothelial cells), and an “other” cell type that included non-584 
identifiable cells, less abundant cells such as macrophages and chondrocytes, and ‘normal’ 585 
pneumocytes and bronchial epithelial cells.  586 
 587 
Training the deep learning pipeline  588 
To improve neural network generalizability and to avoid overfitting for cell detection and 589 
classification, we trained and tested our pipeline on a variety of sample types, including 590 
diagnostic (  = 100), regional (  = 275) and 133 cores corresponding to 75 TRACERx patients 591 
from TMA slides (63 patients had two cores and 12 patients had a single core). Both cell 592 
detection and classification were trained based on single-cell annotations from pathologists. 593 
Two thoracic pathologists annotated 26,960 cells on 53 whole slide images (3 TMAs, 35 594 
regional slides and 15 diagnostic slides) to incorporate morphological variations in 595 
appearance of various cell types and stain variability. Several hundred examples of each cell 596 
class were marked on 76 cores selected at random from TMA images. In total, 4,056, 5,310, 597 
15,007, 2,587 annotations were collected for stromal cells, lymphocytes, cancer cells and 598 
“other” cell types, respectively. These whole slide images were divided into small tile images 599 
of size 2000×2000 pixels (each pixel = 0.5µm), which were then divided into three sample 600 
sets maintaining the class distribution of cells. These included: 13 diagnostic, 58 regional 601 
and 134 TMA tile images for training; 4 diagnostic, 21 regional and 72 TMA tile images for 602 
validation; and 3 diagnostic, 22 regional and 61 TMA tile images for testing. As a result, the 603 
annotations were divided between the three groups; 2/3 for training, 1/6 for validation and 604 
1/6 for testing. The training set included annotations for 2,147 stromal cells, 3,183 605 
lymphocytes, 10,103 cancer and 1,357 other cell types. The validation set had annotations 606 
for 473 stromal cells, 825 lymphocytes, 2,562 tumor and 359 other cell types. Breakdown 607 
for the test set is provided in Supplementary Table 2. 608 
 609 
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For IHC cell classification, we used a pretrained SCCNN network on samples stained for 610 
CD4/CD8/FOXP3. The training set consisted of 1,657 CD4+FOXP3-, 3,187 CD8+, 1,001 611 
CD4+FOXP3+, and 3,488 other (negative) cells. The trained network was tested on 5,028 cell 612 
annotations collected on 6 lung diagnostic whole slide images, including 251 CD4+FOXP3-, 613 
406 CD8+, 123 CD4+FOXP3+ and 4,248 other cells to test the ability of the algorithm in 614 
correctly detecting and classifying negative cells. See Supplementary Table 7 for the total 615 
number of identified cells in the H&E diagnostic, H&E multi-region and IHC diagnostic 616 
datasets.  617 
 618 
Validation of the H&E deep learning pipeline with orthogonal data types 619 
The algorithms’ performance in detecting and classifying single cells in H&E were first 620 
evaluated against the test set of 5951 cells. Individual class accuracy statistics were 621 
calculated using the R function ‘confusionMatrix’ from the R package ‘caret’. 622 
 623 
Pathology TIL estimates were scored following the international guidelines developed by the 624 
International Immuno-Oncology Biomarker Working Group7. Briefly, by inspection of H&E 625 
slide of a given tumor region, the fraction of the stromal area infiltrated by TILs was 626 
assessed.  627 
 628 
For regional samples, tumor cellularity, estimated as the computed percentage cancer cells 629 
was correlated with tumor purity estimated by ASCAT based on DNA-seq copy number and 630 
VAF purity (both available from Jamal-Hanjani et al.6,  = 239 regional tumor samples). The 631 
RNA-seq-based CD8+ T cell signature (available from Rosenthal et al.1, computed using the 632 
Danaher et al. method30) was correlated with the deep learning based lymphocyte 633 
percentage for 142 regional tumor samples. For diagnostic samples, deep learning-based 634 
lymphocyte percentage from H&E was correlated with deep learning-based CD8+ cell 635 
percentage from IHC (  = 100 diagnostic samples, Extended Data Fig. 2a-d).   636 
 637 
Discordance rate between RNA-seq based1 and histology/deep learning-based immune hot 638 
and cold regional classification was calculated by cross-tabulation of immune hot and cold 639 
(from histology) versus high and low (from RNA-seq), disregarding any regions without one 640 
of these two types of data. The RNA-seq method used 15 immune cell signatures presenting 641 
different T- and B-cell subsets, as well as neutrophils, macrophages, mast and dendritic cells, 642 
to classify tumor regions into high and low categories. A Fisher’s exact test was used to 643 
compute the overlap between the two immune classifications. Distributions of multiple 644 
immune scores (lymphocyte percentage, intra-tumor lymphocytes and adjacent-tumor 645 
lymphocytes/stroma) as well as ASCAT tumor purity were compared between hot versus 646 
cold (deep learning) and high versus low (RNA-seq) classifications (Extended Data Fig. 5).  647 
 648 
Validation of the deep learning pipeline with the independent LATTICe-A cohort 649 
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The external validity of the proposed deep learning pipeline was performed on 100 650 
randomly selected patients from the LATTICe-A cohort8. This validation ensures that the 651 
trained cell detection and cell classification models from the TRACERx tumor blocks are 652 
generalizable to a distinct dataset which is processed, stained and scanned in another 653 
center (the LATTICe-A study, University of Leicester).  654 
 655 
All 100 whole-tumor H&E sections were processed using the same TRACERx trained model. 656 
The validation was then performed using two data types. First, a pathologist provided 5,082 657 
single-cell annotations following the same protocol for TRACERx in 20 randomly selected 658 
LATTICe-A sections. The breakdown for single-cell annotations was 1,997 stromal cells, 787 659 
lymphocyte cells, 1,839 cancer cells and 459 other cells (see Supplementary Table 3). 660 
Second, two independent pathologists jointly scored the remaining 80 sections for overall 661 
fraction of lymphocytic infiltration and pathology TIL estimates7. These manual scores were 662 
correlated with the deep learning-based lymphocyte percentage and adjacent-tumor 663 
lymphocytes/total stroma (Extended Data Fig. 2e).  664 
 665 
Validation of the deep learning pipeline with biological assays 666 
A new biological validation method was developed to overcome the challenge of obtaining 667 
large quantities of cell-specific validation data (Fig. 1f-h, Extended Data Fig. 2f-g). 48 cores 668 
were available for the TTF1-H&E image pairs, 38 for the CD45-H&E pairs, and 33 for the 669 
SMA-H&E pairs. Stains were performed using a Ventana BenchMark ULTRA instrument 670 
(H&E, TTF-1) or a Dako Link 48 (CD-45, SMA). Digital images were acquired using a 671 
Hamamatsu Nanozoomer slide scanner. First, H&E staining was performed using a Leica 672 
Infinity kit, and a digital image was collected. The slide was subsequently de-coverslipped, 673 
the H&E stain removed by acid alcohol washing, and then an immunohistochemical stain 674 
with haematoxylin counterstain was applied using a standard diagnostic antigen retrieval 675 
and antibody protocol. A second digital image was acquired after mounting and 676 
coverslipping. Through experimentation, no difference in the staining was observed when 677 
the procedure was reversed.  678 
 679 
TTF-1 (type: Novocastra Liquid Mouse Monoclonal antibody thyroid transcription factor 1, 680 
clone: SPT24, cat. no.: NCL-L-TTF-1, source: Leica biosystems, Germany, used at 1:100) was 681 
selected as the cancer cell marker in these LUAD samples because it is the most robust and 682 
widely used immunohistochemical marker of LUAD cells31. It is very specific, both in that 683 
only epithelial cells are stained in the lung, and in that very few tumors of non-lung or 684 
thyroid origin are stained32. The sensitivity of the antibody clone used (SPT24) is also high, 685 
staining >75% of tumor cells in 76% of LUAD tumors in one published series33. However, as 686 
this implies, there are many tumors in which tumor cell staining is incomplete (i.e. <100%). 687 
Therefore, only cores showing near-universal TTF-1-positivity of tumor cells were used for 688 
validation, in order to provide the best possible ‘gold standard’ comparator for the deep 689 
learning algorithm. The same procedure was followed for pairs of H&E-CD45 (anti-human 690 
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CD45, type: Mouse Monoclonal, clone: 2B11 + PD7/26, cat. no.: M0701, source: Agilent 691 
DAKO, USA, used at 1:200) and H&E-SMA (myofibroblast marker, type: Mouse Monoclonal 692 
antibody Smooth Muscle Actin (1A4), cat. no.: 760-2833, source: Roche, Switzerland, a 693 
ready to use antibody) to biologically validate the accuracy of single cell classification.  694 
 695 
In total, 64,976 TTF1+ cells, 26,284 CD45+ cells and 46,343 SMA+ cells were detected from 696 
the IHC images, denoting the advantage of this method in acquiring large amount of 697 
validation data at single-cell resolution. The correlation measured (Fig. 1f-h, Extended Data 698 
Fig. 2g) was that between the fraction of classified cells in the H&E versus fraction of 699 
positively stained IHC cells per 100µm2.  700 
 701 
Immune phenotype classification  702 
To classify tumor regions into different immune phenotypes, we assigned each region to an 703 
immune hot, cold or intermediate category based on lymphocyte percentage. The 704 
dependency of our subsequently results on thresholds chosen for this classification scheme 705 
was tested after applying perturbations to the thresholds used. Four new classification 706 
schemes were tested: no intermediate zone (i.e. using median lymphocyte percentage for 707 
separating hot and cold regions), regions with lymphocyte percentage greater than standard 708 
deviation/2 above/below the median lymphocyte percentage classified as immune hot/cold,  709 
, and similarly for standard deviation/3 and standard deviation/6 (Extended Data Fig. 4a-b). 710 
For every new classification, we repeated the multivariate survival analysis to confirm the 711 
significance of the number of immune cold regions in predicting disease-free survival as well 712 
as the genomic distance test for pairs of immune hot versus immune cold regions in LUAD 713 
patients (Extended Data Fig. 4b). In addition, the CD8+ RNA-seq signature was used to test 714 
the difference in CD8+ levels between immune hot and immune cold phenotypes across all 715 
classification schemes (Extended Data Fig. 4c).  716 
 717 
Genomic distance measure 718 
Genomic distance was calculated as described previously1, by taking the Euclidean distance 719 
of the mutations present for every pair of immune hot and immune cold regions from the 720 
same patient. All mutations present in a region from a tumor were turned into a binary 721 
matrix of which the rows were mutations and columns were the tumor regions. From this 722 
matrix, the pairwise distance was determined. 723 
 724 
Distance between dominant clones to the last common ancestor of region pair 725 
Deep learning-based immune phenotypes were integrated with the TRACERx phylogenetics 726 
data6. Dominant clones (using the upper quartile of cancer cell fraction, ≥ 75%) were 727 
labelled for all tumor regions’ trees which had an available H&E sample in LUAD patients (  728 
= 76 regions, 15 immune hot pairs and 23 immune cold pairs). For every pair of immune hot 729 
/ cold regions within a tumor, the distance between the dominant clones (as measured by 730 
branch length, i.e. number of mutations) via their last common ancestor was computed. The 731 
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recently shared ancestry clone between the two dominant clones was labelled as the ‘last 732 
common ancestor of region pair’ (annotated with arrows in Fig 3.c). To ensure this analysis 733 
was not dependent on a certain cancer cell fraction threshold, multiple thresholds (CCF ≥ 734 
80%, 85%) were placed while repeating the same analysis. Next, by identifying the last 735 
common ancestral subclone for pairs of the same phenotype, each pair was categorized into 736 
one of two diversification patterns: ‘diversifying at the most recent common ancestor 737 
(MRCA) of the tree’ or ‘diversifying at a descendant subclone of the MRCA of the tree’. The 738 
latter category included a pattern exclusive to immune cold pairs, where the two regions 739 
shared the same dominant subclone that was the direct descendant of the MRCA of the 740 
tree. 741 
 742 
Tumor spatial modelling 743 
H&E and IHC cell abundance scores (e.g. lymphocyte percentage, CD8+ percentage) were 744 
computed as the percentage of a cell type in the total sample cell count. Stromal TILs were 745 
identified using spatial modelling20,34,35, where lymphocytes were classified (using 746 
unsupervised clustering) into intra-tumor lymphocytes, adjacent-tumor lymphocytes and 747 
distal-tumor lymphocytes based on their spatial proximity to epithelial cell nests in H&Es. 748 
The immune hotspot score was calculated using the Getis–Ord algorithm as previously 749 
described36. To capture the emergence of complex morphological patterns that dictate 750 
cancer-stromal cell spatial contact preserved over varying spatial scales, a fractal dimension 751 
calculation (Minkowski-Bouligand dimension) was performed using the box-counting 752 
algorithm37. This algorithm calculates the number of boxes of a certain size needed to cover 753 
a geometric pattern. We modified a MATLAB-based algorithm38 to include both spatial 754 
information of cancer and stromal cells, as opposed to its conventional use on one variable 755 
(i.e. pixel information of an image). The analysis was carried out on spatial maps generated 756 
using coordinates of classified stromal and cancer cells, while utilizing the tissue segmented 757 
image (as a boundary mask) to exclude all empty tissue areas. Choices of box size were 758 
informed by the distribution of minimum and maximum Euclidean distance for each stromal 759 
cell to its nearest cancer cell in all 275 tumor regions (Extended Data Fig. 7a). The mean 760 
minimum distance was 21.43µm. We limited the upper box size at 300µm, which is just 761 
above a previously proposed cell-cell communication distance of 250μm39 but designed to 762 
be more inclusive. For statistical tests where fractal dimension was represented at tumor 763 
level, the maximum regional score was used.  764 
 765 
H&E-IHC spatial alignment/immune subset projection 766 
For a H&E diagnostic slide, we determined the number of intra-tumor lymphocytes, 767 
adjacent-tumor lymphocytes and distal-tumor lymphocytes (nI, nA, nD) based on spatial 768 
modelling of the H&Es. After spatial alignment of IHC and projecting IHC-derived cells onto 769 
the H&E, the number of CD8+ cells that were also intra-tumor lymphocytes was determined 770 
(nCD8ITL), and similarly for other cell types. As a result, intra-tumor lymphocytes were 771 
deconvoluted by nI = nCD8I + nCD4I + nFOXP3I + notherI. Two-sided paired Wilcox was used to test the 772 
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difference in the percentage of CD8+ cells among intra-tumor lymphocytes, adjacent-tumor 773 
lymphocytes and distal-tumor lymphocytes (nCD8ATL, nCD8DTL, nCD8ITL).  The same test was performed 774 
for CD4+FOXP3- and CD4+FOXP3+ cells.  775 
 776 
The 10 LUAD patients with the highest adjacent-tumor lymphocytes to stromal cell ratio 777 
were selected for this immune subset spatial projection. All samples had above median 778 
CD8+%. One sample was excluded due to poor HE-IHC alignment quality and the subsequent 779 
analysis was performed on the remaining nine samples. The quality of alignment was 780 
evaluated by manually identifying 238 visible landmarks and placed on corresponding 781 
positions in H&E and IHC tiles (total number of tiles = 249, maximum landmarks per tile = 5), 782 
as shown in Extended Data Fig. 8b. These marked points were used to compute the 783 
Euclidean distance (difference in ,  coordinates) between them to obtain a quantitative 784 
measurement of alignment accuracy. The average distance between matching landmarks 785 
was 9.57µm, whereas the maximum distance between the H&E and CD4/CD8/FOXP3 786 
sections was 16µm.  787 
 788 
Survival analysis and other statistical methods 789 
Survival tests were conducted using Kaplan-Meier estimator (‘ggsurvplot’ R function from 790 
the ‘survminer’ and ‘survival’ R packages) as well as Cox model (‘coxph’ R function and 791 
displayed using ‘ggforest’ R function). Forest plots show the hazard ratio in the x-axis; each 792 
variable’s hazard ratio is plotted and annotated with a 95% confidence interval. The clinical 793 
parameters included in the multivariate model were age, sex, smoking pack years, histology 794 
(whether LUAD, LUSC or otherwise), tumor stage, adjuvant therapy (whether received or 795 
not). Because of its prognostic importance in TRACERx, the upper quartile of clonal 796 
neoantigens in each histology cohort was also incorporated in the multivariate model. The 797 
range of available disease-free survival data was 34-1364 days (median = 915 days) in 798 
TRACERx, and 1-6139 days (median = 684 days) in LATTICe-A. All hazard ratios were 799 
computed on all time points (i.e. the whole survival curve, not at a specific time point). 800 
Correlation tests used Spearman’s method and were generated using the function 801 
‘ggscatter’ from the ‘ggpubr’ R package. All correlation plots show the Rho (ρ) coefficient 802 
and the significance -value. For statistical comparisons among groups, a two-sided, non-803 
parametric, unpaired, Wilcoxon signed-rank test was used, unless stated otherwise. All box 804 
plots were generated using the function ‘ggboxplot’ from the ‘ggpubr’ R package (all data 805 
points are plotted with the ‘jitter’ option, the median value is indicated by a thick horizontal 806 
line; minimum and maximum values are indicated by the extreme points; the first and third 807 
quantiles are represented by the box edges; and vertical lines indicate the error range) or 808 
the function ‘ggbetweenstats’ from the ‘ggstatplot’ R package for more than two groups. 809 
Tests for concordance between two data classes were analyzed using a Fisher’s exact test. 810 
All statistical tests were two-sided, a  value of less than .05 was considered statistically 811 
significant. To adjust -values for multiple comparisons, the Benjamini & Hochberg method 812 
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was used. To measure effect size, Cohen’s d method was used. All statistical analyses were 813 
conducted in R (version 3.5.1).  814 
 815 
Reporting summary 816 
Further information on research design is available in the Nature Research Reporting 817 
Summary linked to this paper. 818 
  819 
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Extended Data Figures legends 820 
 821 
Extended Data Fig. 1. CONSORT diagrams for TRACERx 100 and LATTICe-A histology 822 
cohorts and patient characteristics. a. TRACERx CONSORT diagram to illustrate sample 823 
collection and analysis of regional and diagnostic histology samples, as well as the overlap 824 
with RNA and DNA studies. b. TRACERx patient characteristics for the histology cohort. c. 825 
LATTICe-A CONSORT diagram (  = 970 LUAD patients). Legends for ‘type of the analysis’ 826 
correspond to panel a. d. Demographics and clinical patient characteristics for TRACERx (top 827 
three panels) and LATTICe-A (bottom three panels) showing the distribution of age (colored 828 
by sex), distribution of smoking pack years and the proportion of patients in each 829 
pathological stage. Horizontal lines indicate the median value. 830 
 831 
Extended Data Fig. 2. Validation of the automated single-cell classification for H&E. a. A 832 
scatter plot showing the correlation between H&E-based adjacent-tumor 833 
lymphocytes/stromal and pathology TIL estimates in diagnostic samples (  = 98 diagnostic 834 
slides/patients).  b. Scatter plots showing the correlations between H&E-based tumor 835 
cellularity estimate and ASCAT/VAF purity scores (  = 238 regions; 83 patients). c. A scatter 836 
plot showing the correlation between H&E-based estimate of lymphocyte percentage 837 
among all cells and RNA-seq-based CD8+ signature using the Danaher et al. method30 (  = 838 
142 regions; 56 patients).  d. A scatter plot showing the correlation between H&E-based 839 
estimate of lymphocyte percentage among all cells and CD8+ cell percentage in IHC in the 840 
diagnostic samples (  = 100 diagnostic slide/patients). e. Scatter plots showing the 841 
correlation between H&E-based lymphocyte percentage versus pathological scores of 842 
overall lymphocytic cell fraction, and adjacent-tumor lymphocytes/stromal versus pathology 843 
TIL estimates in an external cohort (LATTICe-A,  = 80 diagnostic slides/patients). f. 844 
Illustrative example to show the spatial alignment of TTF1/CD45/SMA-stained IHC and H&E 845 
images obtained using sequential staining on the same tissue microarray section for 846 
biological validation. g. A scatter plot showing the correlation between stromal cell 847 
percentage determined by H&E and SMA+ cell percentage per LUAD image tiles of size 848 
100µm2 (  = 144). The experiment was conducted once using one TMA (  = 33 849 
cores/patients). The shading indicates 95% confidence interval. 850 
 851 
Extended Data Fig. 3. Distribution of regional lymphocytic infiltration according to 852 
pathological stage. All available patients’ data have been used in this figure except for the 853 
standard deviation tests excluding patients with a single tumor region. Patients without 854 
pathological staging information from the LATTICe-A cohort were also removed. a, b, c, top 855 
row: TRACERx and bottom row: LATTICe-A. Horizontal lines indicate the median value. a. 856 
Distribution of the standard deviation of regional lymphocyte percentage for LUAD and 857 
LUSC patients in TRACERx (  = 69), and LUAD in LATTICe-A (  = 814). b. Distribution of the 858 
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standard deviation of regional lymphocyte percentage across pathological stages (  = 69 for 859 
TRACERx, 814 for LATTICe-A). c. Distribution of regional mean of lymphocyte percentage 860 
across stages (  = 79 for TRACERx, 827 for LATTICe-A). d. No significant difference among 861 
stages with respect to standard deviation (  = 69 for TRACERx, 814 for LATTICe-A) or mean 862 
(  = 79 for TRACERx, 827 for LATTICe-A) of regional lymphocytic infiltration. Left panel, 863 
TRACERx and right panel, LATTICe-A. Correction for multiple testing was applied in d, for 864 
each cohort individually. A two-sided, non-parametric, unpaired, Wilcoxon signed-rank test 865 
was used; each dot represents a patient; the mean value is annotated with a large dot; the 866 
median value is represented by a thick horizontal line; minimum and maximum values are 867 
indicated by the extreme points; the first and third quantiles are represented by the box 868 
edges; and the violin shape shows the data distribution as a kernel density estimation. 869 
 870 
Extended Data Fig. 4. Validation of immune phenotype classification. a. The proposed 871 
immune classification imposed on density plot showing distribution of lymphocyte 872 
percentage. The middle zone corresponds to the intermediate phenotype, red zone for 873 
immune hot and blue zone for immune cold. Black dash line shows the median. This 874 
classification was validated after applying small perturbations to the thresholds to re-classify 875 
regional immune phenotypes, illustrated as grey dash lines: no intermediate zone (i.e. hard 876 
median for separating hot and cold), standard deviation (SD)/2 above and below the 877 
median, SD/3 and SD/6. b. Forest plots to show repeated multivariate Cox regression tests 878 
for the number of immune cold regions using these new classifications (  = 79 patients), 879 
after accounting for stage, total number of samples, upper quartile of clonal neoantigens 880 
determined for LUAD and LUSC individually, and other clinical parameters. Box plots 881 
showing difference in genomic distance for pairs of hot regions compared with pairs of cold 882 
regions for LUAD and LUSC separately (LUAD:  = 45 hot pairs, 45 cold pairs for no 883 
intermediate zone;  = 19 hot, 25 cold for SD/2;  = 25 hot, 33 cold for SD/3;  = 32 hot, 41 884 
cold for SD/6. LUSC:  = 32 hot pairs, 54 cold pairs for no intermediate zone;  = 19 hot, 27 885 
cold for SD/2;  = 19 hot, 37 cold for SD/3;  = 27 hot, 41 cold for SD/6.). c. Box plots 886 
showing significant difference in CD8+ RNA-seq signature using the Danaher method 887 
between regions of hot and cold phenotype across all classification schemes (  = 219 for 888 
SD/4; 275 for no intermediate zone; 173 for SD/2; 204 for SD/3; 237 for SD/6). d. 889 
Distribution and difference of lymphocytic infiltration for LUAD versus LUSC regions in 890 
TRACERx (  = 275 regions; 85 patients) as well as distribution for LUAD in LATTICe-A (  = 891 
4,324 samples; 970 patients). Horizontal lines in the distribution plots indicate mean values. 892 
For statistical comparisons among groups, a two-sided, non-parametric, unpaired, Wilcoxon 893 
signed-rank test was used, unless stated otherwise. 894 
 895 
Extended Data Fig. 5. Concordance between histology deep learning and RNA-seq immune 896 
classification. a. A box plot showing the difference in pathology TIL estimates between 897 
 27
immune hot and immune cold regions (  = 219). Pathology TIL estimates score fraction of 898 
stroma containing TILs, whereas immune classification was defined based on the percentage 899 
of lymphocytes in all cells within a slide. b. A confusion matrix to compare RNA-seq and 900 
deep learning histology immune classifications (discarding immune intermediate regions,  901 
= 109 regions (57 LUAD, 37 LUSC, 15 other histology subtypes); 52 patients). The p-value 902 
was generated using a two-sided Fisher’s exact test for overlap. c. A box plot showing the 903 
difference in the fraction of immune hotspots36 in regions where the two classifications are 904 
in agreement (  = 78; labeled as ‘In agreement’) against the discrepant regions (  = 31, 905 
labeled as ‘Discrepant’). Each dot represents a region, the median value is indicated by a 906 
thick horizontal line; minimum and maximum values are indicated by the extreme points; 907 
and the first and third quantiles are represented by the box edges. d. Box plots to support 908 
the overall consistency between H&E-deep learning and RNA-seq methods by comparing 909 
different immune scores as well as ASCAT tumor purity between immune hot/high and 910 
cold/low tumor regions (all 	-values < 0.0001). Top row, H&E-deep learning immune 911 
classification (  = 219; except the ASCAT purity box plot  = 186 regions), bottom row, RNA-912 
seq derived immune classification (  = 142; except the ASCAT purity box plot,  = 141 913 
regions). For statistical comparisons among groups, a two-sided, non-parametric, unpaired, 914 
Wilcoxon signed-rank test was used, unless stated otherwise. 915 
 916 
Extended Data Fig. 6. Genomic and survival analysis of tumor regions according to 917 
immune phenotypes. a. A box plot showing the difference in genomic distances for pairs of 918 
immune hot versus immune cold regions within the same LUSC patients (  = 59 pairs). A 919 
two-sided, non-parametric, unpaired, Wilcoxon signed-rank test was used. b. Forest plots to 920 
show the univariate prognostic value for the number of immune low regions (both as 921 
continuous and dichotomized at the median (≤1 versus >1)), or the number of immune high 922 
regions, using the immune classification generated by RNA-seq-based infiltrating immune 923 
cell populations1 in 64 TRACERx tumors (41 LUAD, 16 LUSC and 7 other histology subtypes). 924 
c. Forest plots showing multivariate Cox regression analyses in both TRACERx (  = 79 925 
patients; LUAD and LUSC combined) and LATTICe-A (  = 651 LUAD patients representing a 926 
subset with complete stage and smoking pack years data) with the number of immune cold 927 
regions dichotomized at the median (≤1 versus >1). This remains significant when the 928 
number of immune cold regions was replaced as a continuous variable, in the same 929 
multivariate model, (	 = 0.019 in TRACERx and < 0.001 in LATTICe-A, for the number of 930 
immune cold regions). Clonal neoantigens were dichotomized using the upper quartile, 931 
determined individually for LUAD and LUSC tumors1. d. The same test in c when tumor size 932 
(in mm) was also controlled in the multivariate model in LATTICe-A. This test also remained 933 
significant for a bigger group of patients with complete stage data, but missing pack years 934 
information (  = 815,  < 0.001, HR = 1.4[1.1-1.8]). e. Forest plots to compare the prognostic 935 
value of regional immune scores as well as diagnostic H&E and IHC scores for relapse-free 936 
survival in TRACERx (  = 79 patients, LUAD and LUSC combined). Wherever possible, these 937 
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immune features were tested in LATTICe-A (  = 970 patients). To compare the prognostic 938 
value of the number of immune cold region with other immune features, LATTICe-A 939 
comparisons were conducted in Cox multivariate regression models to include every 940 
immune feature after correcting for the number of immune cold regions in the same model. 941 
Each variable’s HR is plotted with a 95% confidence interval; all -values were adjusted for 942 
multiple testing; and the size of the circles denotes –log10(	). For the sake of visualization, 943 
a minor adjustment was made to the HR for the number of cold regions/total number of 944 
regions in LATTICe-A from 0.88[0.57-1.3] to 0.99[0.97-1.3]. SD: standard deviation, used for 945 
measuring variability of lymphocyte percentage among samples within a tumor. f. Forest 946 
plots using Cox multivariate regression analysis showing that the prognostic value of the  947 
number of immune cold regions was independent of: 1) genetic measure, subclonal copy 948 
number alteration (obtained from 6); 2) tumor cellularity from DNA-seq-based ASCAT purity, 949 
3) tumor cellularity measured by deep learning-based cancer cell percentage. g. Kaplan 950 
Meier curves to illustrate the difference in relapse-free survival for TRACERx patients 951 
including other histology types (  = 85; representing all TRACERx patients in the multi-952 
region histology cohort) with high and low number of immune cold regions, dichotomized 953 
by its median value. Log-rank  = 0.0017. h. Forest plot using Cox regression for the 954 
multivariate survival analysis for the number of immune cold regions in TRACERx including 955 
patients with other histology subtypes (  = 85). 956 
 957 
Extended Data Fig. 7. Fractal dimension and relationships with stromal cells. a. 958 
Distribution of the average minimum Euclidean distance between a stromal cell to its 959 
neighboring cancer cell. For every stromal cell in a tumor region slide, the minimum distance 960 
to nearest cancer cell was computed. This distance was then averaged for all identified 961 
stromal cells in every region to plot the distribution (  = 275 regions; 85 patients). b. 962 
Distribution of the fractal dimension of the cancer-stroma cell interface for histology types 963 
in the TRACERx cohort (  = 275 regions; 85 patients). c. Box plots to show the difference in 964 
fractal dimension between immune hot and cold regions in TRACERx LUAD (  = 113) and 965 
LUSC (  = 84). d. Box plots showing the difference in stromal cell percentage between 966 
immune hot and cold regions in all (  = 219), LUAD (  = 113), and LUSC (  = 84). e. Scatter 967 
plots showing the correlation between fractal dimension and percentage of cells that are 968 
stromal or cancer in all tumor regions (  = 275 regions; 85 patients). This shows that fractal 969 
dimension was independent of tumor cell composition, with only a weak correlation with 970 
stromal cell percentage and no correlation with tumor cellularity. f. Box plots showing the 971 
difference in fractal dimension between LUAD tumor regions harboring an LOH event for 972 
HLA type A (  = 106), type B (  = 113), type C (  = 108) versus regions that do not, adjusted 973 
for multiple comparisons with the corresponding test in Fig. 4c. g. The same test in f 974 
repeated for LUSC tumor regions (  = 87) for HLA of any type. h. Box plots showing the 975 
difference in tumor-level fractal dimension using the maximum value of regional measures 976 
between LUAD tumors (  = 48) harboring a single LOH event for any HLA type, HLA type A, 977 
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type B and type C versus tumors that do not, independent of predicted clonal neoantigens. 978 
Each p-value was generated using a multiple regression linear model and was also adjusted 979 
for multiple testing correction. i. The same test in h repeated for LUSC tumors (  = 29) for 980 
HLA of any type. For statistical comparisons among groups, a two-sided, non-parametric, 981 
unpaired, Wilcoxon signed-rank test was used, unless stated otherwise. 982 
 983 
Extended Data Fig. 8. Relationship of immune subsets and spatial TILs in LUAD. a. 984 
Spearman’s correlations between immune scores in diagnostic slides and genetic measures 985 
including predicted neoantigens and HLALOH in LUAD patients (  = 46). ITLR: intra-tumor 986 
lymphocytes to total tumor cell ratio. Only significant correlations after multiple testing are 987 
highlighted (rho = 0.37, 	 = 0.035). b. Examples of registered H&E and IHC tiles. The green 988 
cross denotes a manually placed landmark repeated 238 times on pairs of H&E-IHC image 989 
tiles. The Euclidean distance (difference in ,  coordinates) was computed between the two 990 
landmarks which was then c. shown as a distribution to represent the accuracy of the 991 
registration (  = 249 total H&E-IHC image tiles, maximum five landmarks per a pair of tiles). 992 
The average distance between matching landmarks was 9.57µm and the distribution is 993 
within the expected range of maximum distance between four serial sections (16µm). d. Box 994 
plots to illustrate the difference in percentage of immune cell subsets among adjacent, intra 995 
and distal-tumor lymphocytes (  = 20 image tiles), a non-parametric, paired Wilcoxon test 996 
was used. 997 
 998 
Extended Data Fig. 9. Summary of immune and genomics features in NSCLC. An extended 999 
heatmap showing all immune variables described in TRACERx across all patients (  = 275 1000 
regions; 85 patients), along with genetic measures and clinical parameters. Each column 1001 
represents a tumor, grouped by their histologic subtype. Tumor regions (illustrated as dots) 1002 
were assigned to immune hot, immune cold and intermediate phenotypes based on 1003 
percentage of lymphocytes in all cells following H&E-based deep learning analysis. Cancer-1004 
stromal fractal dimension, defined using the maximum fractal dimension in regions of a 1005 
patient, using the median as cut-off to determine high and low groups. 1006 
  1007 
 30
Methods and Extended Data References  1008 
 1009 
27. Raza, S. E. A. et al. Micro-Net: A unified model for segmentation of various objects in 1010 
microscopy images. Med. Image Anal. 52, 160–173 (2019). 1011 
28. Sirinukunwattana, K. et al. Locality Sensitive Deep Learning for Detection and 1012 
Classification of Nuclei in Routine Colon Cancer Histology Images. IEEE Trans. Med. Imaging 1013 
35, 1196–1206 (2016). 1014 
29. Abadi, M. et al. TensorFlow: Large-Scale Machine Learning on Heterogeneous 1015 
Distributed Systems. (2016). 1016 
30. Danaher, P. et al. Gene expression markers of Tumor Infiltrating Leukocytes. J. 1017 
Immunother. Cancer 5, 18 (2017). 1018 
31. HOLZINGER, A. et al. Monoclonal Antibody to Thyroid Transcription Factor-1: 1019 
Production, Characterization, and Usefulness in Tumor Diagnosis. Hybridoma 15, 49–53 1020 
(1996). 1021 
32. Matoso, A. et al. Comparison of thyroid transcription factor-1 expression by 2 1022 
monoclonal antibodies in pulmonary and nonpulmonary primary tumors. Appl. 1023 
Immunohistochem. Mol. Morphol.  AIMM 18, 142–9 (2010). 1024 
33. Pelosi, G. et al. ΔNp63 (p40) and Thyroid Transcription Factor-1 Immunoreactivity on 1025 
Small Biopsies or Cellblocks for Typing Non-small Cell Lung Cancer: A Novel Two-Hit, 1026 
Sparing-Material Approach. J. Thorac. Oncol. 7, 281–290 (2012). 1027 
34. Heindl, A. et al. Relevance of Spatial Heterogeneity of Immune Infiltration for 1028 
Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer. JNCI J. Natl. 1029 
Cancer Inst. 110, (2018). 1030 
35. Heindl, A. et al. Microenvironmental niche divergence shapes BRCA1-dysregulated 1031 
ovarian cancer morphological plasticity. Nat. Commun. 9, 3917 (2018). 1032 
36. Nawaz, S., Heindl, A., Koelble, K. & Yuan, Y. Beyond immune density: critical role of 1033 
spatial heterogeneity in estrogen receptor-negative breast cancer. Mod. Pathol. 28, 766–1034 
777 (2015). 1035 
37. Dubuc, Quiniou, Roques-Carmes, Tricot & Zucker. Evaluating the fractal dimension of 1036 
profiles. Phys. Rev. A, Gen. Phys. 39, 1500–1512 (1989). 1037 
38. MOISY, F. & JIMÉNEZ, J. Geometry and clustering of intense structures in isotropic 1038 
turbulence. J. Fluid Mech. 513, 111–133 (2004). 1039 
39. Francis, K. & Palsson, B. O. Effective intercellular communication distances are 1040 
determined by the relative time constants for cyto/chemokine secretion and diffusion. Proc. 1041 
Natl. Acad. Sci. U. S. A. 94, 12258–62 (1997). 1042 







1. Rosenthal, R. et al. Neoantigen-directed immune escape in lung cancer evolution. 1048 
Nature 1 (2019). doi:10.1038/s41586-019-1032-7 1049 
2. Morris, L. G. T. & Chan, T. A. Lung Cancer Evolution: What’s Immunity Got to Do with 1050 
It? Cancer Cell 35, 711–713 (2019). 1051 
3. Morris, L. G. T. et al. Pan-cancer analysis of intratumor heterogeneity as a prognostic 1052 
determinant of survival. Oncotarget 7, 10051–10063 (2016). 1053 
4. Milo, I. et al. The immune system profoundly restricts intratumor genetic 1054 
heterogeneity. Sci. Immunol. 3, (2018). 1055 
5. Jia, Q. et al. Local mutational diversity drives intratumoral immune heterogeneity in 1056 
non-small cell lung cancer. Nat. Commun. 9, (2018). 1057 
6. Jamal-Hanjani, M. et al. Tracking the Evolution of Non–Small-Cell Lung Cancer. N. 1058 
Engl. J. Med. 376, 2109–2121 (2017). 1059 
7. Hendry, S. et al. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors. Adv. Anat. 1060 
Pathol. 24, 311–335 (2017). 1061 
8. Moore, D. A. et al. In situ growth in early lung adenocarcinoma may represent 1062 
precursor growth or invasive clone outgrowth—a clinically relevant distinction. Mod. 1063 
Pathol. 1 (2019). doi:10.1038/s41379-019-0257-1 1064 
9. Whittaker, K. A. & Rynearson, T. A. Evidence for environmental and ecological 1065 
selection in a microbe with no geographic limits to gene flow. Proc. Natl. Acad. Sci. U. 1066 
S. A. 114, 2651–2656 (2017). 1067 
10. Shafer, A. B. A. & Wolf, J. B. W. Widespread evidence for incipient ecological 1068 
speciation: A meta-analysis of isolation-by-ecology. Ecology Letters 16, 940–950 1069 
(2013). 1070 
11. Costa, A. et al. Fibroblast Heterogeneity and Immunosuppressive Environment in 1071 
Human Breast Cancer. Cancer Cell 33, 463-479.e10 (2018). 1072 
12. Öhlund, D. et al. Distinct populations of inflammatory fibroblasts and myofibroblasts 1073 
in pancreatic cancer. J. Exp. Med. 214, 579–596 (2017). 1074 
13. Salmon, H. et al. Matrix architecture defines the preferential localization and 1075 
migration of T cells into the stroma of human lung tumors. J. Clin. Invest. 122, 899–1076 
910 (2012). 1077 
14. Thomas, D. A. & Massagué, J. TGF-β directly targets cytotoxic T cell functions during 1078 
tumor evasion of immune surveillance. Cancer Cell 8, 369–380 (2005). 1079 
15. Joyce, J. A. & Fearon, D. T. T cell exclusion, immune privilege, and the tumor 1080 
microenvironment. Science (80-. ). 348, 74–80 (2015). 1081 
16. Sorokin, L. The impact of the extracellular matrix on inflammation. Nat. Rev. 1082 
Immunol. 10, 712–723 (2010). 1083 
17. Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer–immune set 1084 
point. Nature 541, 321–330 (2017). 1085 
18. McGranahan, N. et al. Allele-Specific HLA Loss and Immune Escape in Lung Cancer 1086 
Evolution. Cell 171, 1259-1271.e11 (2017). 1087 
19. McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity 1088 
to immune checkpoint blockade. Science (80-. ). 351, (2016). 1089 
20. Yuan, Y. Modelling the spatial heterogeneity and molecular correlates of lymphocytic 1090 
infiltration in triple-negative breast cancer. J. R. Soc. Interface 12, 20141153 (2015). 1091 
 33
21. Thomas, A., Liu, S. V., Subramaniam, D. S. & Giaccone, G. Refining the treatment of 1092 
NSCLC according to histological and molecular subtypes. Nat. Rev. Clin. Oncol. 12, 1093 
511–526 (2015). 1094 
22. Hammerman, P. S. et al. Comprehensive genomic characterization of squamous cell 1095 
lung cancers. Nature 489, 519–525 (2012). 1096 
23. Collisson, E. A. et al. Comprehensive molecular profiling of lung adenocarcinoma: The 1097 
cancer genome atlas research network. Nature 511, 543–550 (2014). 1098 
24. Keren, L. et al. A Structured Tumor-Immune Microenvironment in Triple Negative 1099 
Breast Cancer Revealed by Multiplexed Ion Beam Imaging. Cell 174, 1373-1387.e19 1100 
(2018). 1101 
25. Giesen, C. et al. Highly multiplexed imaging of tumor tissues with subcellular 1102 
resolution by mass cytometry. Nat. Methods 11, 417–422 (2014). 1103 
26. Goltsev, Y. et al. Deep Profiling of Mouse Splenic Architecture with CODEX 1104 
Multiplexed Imaging. Cell 174, 968-981.e15 (2018). 1105 
27. Raza, S. E. A. et al. Micro-Net: A unified model for segmentation of various objects in 1106 
microscopy images. Med. Image Anal. 52, 160–173 (2019). 1107 
28. Sirinukunwattana, K. et al. Locality Sensitive Deep Learning for Detection and 1108 
Classification of Nuclei in Routine Colon Cancer Histology Images. IEEE Trans. Med. 1109 
Imaging 35, 1196–1206 (2016). 1110 
29. Abadi, M. et al. TensorFlow: Large-Scale Machine Learning on Heterogeneous 1111 
Distributed Systems. (2016). 1112 
30. Danaher, P. et al. Gene expression markers of Tumor Infiltrating Leukocytes. J. 1113 
Immunother. Cancer 5, 18 (2017). 1114 
31. HOLZINGER, A. et al. Monoclonal Antibody to Thyroid Transcription Factor-1: 1115 
Production, Characterization, and Usefulness in Tumor Diagnosis. Hybridoma 15, 49–1116 
53 (1996). 1117 
32. Matoso, A. et al. Comparison of thyroid transcription factor-1 expression by 2 1118 
monoclonal antibodies in pulmonary and nonpulmonary primary tumors. Appl. 1119 
Immunohistochem. Mol. Morphol.  AIMM 18, 142–9 (2010). 1120 
33. Pelosi, G. et al. ΔNp63 (p40) and Thyroid Transcription Factor-1 Immunoreactivity on 1121 
Small Biopsies or Cellblocks for Typing Non-small Cell Lung Cancer: A Novel Two-Hit, 1122 
Sparing-Material Approach. J. Thorac. Oncol. 7, 281–290 (2012). 1123 
34. Heindl, A. et al. Relevance of Spatial Heterogeneity of Immune Infiltration for 1124 
Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer. JNCI J. 1125 
Natl. Cancer Inst. 110, (2018). 1126 
35. Heindl, A. et al. Microenvironmental niche divergence shapes BRCA1-dysregulated 1127 
ovarian cancer morphological plasticity. Nat. Commun. 9, 3917 (2018). 1128 
36. Nawaz, S., Heindl, A., Koelble, K. & Yuan, Y. Beyond immune density: critical role of 1129 
spatial heterogeneity in estrogen receptor-negative breast cancer. Mod. Pathol. 28, 1130 
766–777 (2015). 1131 
37. Dubuc, Quiniou, Roques-Carmes, Tricot & Zucker. Evaluating the fractal dimension of 1132 
profiles. Phys. Rev. A, Gen. Phys. 39, 1500–1512 (1989). 1133 
38. MOISY, F. & JIMÉNEZ, J. Geometry and clustering of intense structures in isotropic 1134 
turbulence. J. Fluid Mech. 513, 111–133 (2004). 1135 
39. Francis, K. & Palsson, B. O. Effective intercellular communication distances are 1136 
determined by the relative time constants for cyto/chemokine secretion and 1137 
diffusion. Proc. Natl. Acad. Sci. U. S. A. 94, 12258–62 (1997). 1138 
 34
  1139 
 35
Geospatial immune variability illuminates differential evolution of  1140 
lung adenocarcinoma  1141 
 1142 
 1143 
TRACERx consortium member names 1144 
Charles Swanton (3,4,5), Mariam Jamal-Hanjani (3,5), John Le Quesne (10,11,15), Allan 1145 
Hackshaw (12), Sergio A Quezada (13), Nicholas McGranahan (3,14), Rachel Rosenthal (3,4), 1146 
Crispin T Hiley (3,4), Selvaraju Veeriah (3,4), David A Moore (3,6), Maise Al Bakir (4), Teresa 1147 
Marafioti (6), Roberto Salgado (8,9), Yenting Ngai (12), Abigail Sharp (12), Cristina Rodrigues 1148 
(12), Oliver Pressey (12), Sean Smith (12), Nicole Gower (12), Harjot Dhanda (12), Joan Riley 1149 
(16), Lindsay Primrose (16), Luke Martinson (16), Nicolas Carey (16), Jacqui A Shaw (16), 1150 
Dean Fennell (16,28), Gareth A Wilson (17), Nicolai J Birkbak (17), Thomas B K Watkins (17), 1151 
Mickael Escudero (17), Aengus Stewart (17), Andrew Rowan (17), Jacki Goldman (17), Peter 1152 
Van Loo (17), Richard Kevin Stone (17), Tamara Denner (17), Emma Nye (17), Sophia Ward 1153 
(17), Emilia L Lim (17), Stefan Boeing (17), Maria Greco (17), Kevin Litchfield (17), Jerome 1154 
Nicod (17), Clare Puttick (17), Katey Enfield (17), Emma Colliver (17), Brittany Campbell (17), 1155 
Christopher Abbosh (18), Yin Wu (18), Marcin Skrzypski (18), Robert E Hynds (18), Andrew 1156 
Georgiou (18), Mariana Werner Sunderland (18), James L Reading (18), Karl S Peggs (18), 1157 
John A Hartley (18), Pat Gorman (18), Helen L Lowe (18), Leah Ensell (18), Victoria Spanswick 1158 
(18), Angeliki Karamani (18), Dhruva Biswas (18), Maryam Razaq (18), Stephan Beck (18), 1159 
Ariana Huebner (18), Michelle Dietzen (18), Cristina Naceur-Lombardelli (18), Mita Afroza 1160 
Akther (18), Haoran Zhai (18), Nnennaya Kannu (18), Elizabeth Manzano (18), Supreet Kaur 1161 
Bola (18), Ehsan Ghorani (18), Marc Robert de Massy (18), Elena Hoxha (18), Emine 1162 
Hatipoglu (18), Stephanie Ogwuru (18), Benny Chain (18), Gillian Price (19), Sylvie Dubois-1163 
Marshall (19), Keith Kerr (19), Shirley Palmer (19), Heather Cheyne (19), Joy Miller (19), 1164 
Keith Buchan (19), Mahendran Chetty (19), Mohammed Khalil (19), Veni Ezhil (20), Vineet 1165 
Prakash (20), Girija Anand (21), Sajid Khan (21), Kelvin Lau (22), Michael Sheaff (22), Peter 1166 
Schmid (22), Louise Lim (22), John Conibear (22), Roland Schwarz (23,24,25), Jonathan 1167 
Tugwood (26), Jackie Pierce (26), Caroline Dive (26,27), Ged Brady (26,27), Dominic G 1168 
Rothwell (26,27), Francesca Chemi (26,27), Elaine Kilgour (26,27), Fiona Blackhall (27,30), 1169 
Lynsey Priest (27,30), Matthew G Krebs (27,30), Philip Crosbie (27,51,52), Apostolos Nakas 1170 
(28), Sridhar Rathinam (28), Louise Nelson (28), Kim Ryanna (28), Mohamad Tuffail (28), 1171 
Amrita Bajaj (28), Jan Brozik (28), Fiona Morgan (29), Malgorzata Kornaszewska (29), Richard 1172 
Attanoos (29), Haydn Adams (29), Helen Davies (29), Mathew Carter (30), Lindsay CR (30), 1173 
Fabio Gomes (30), Zoltan Szallasi (31), Istvan Csabai (32), Miklos Diossy (32), Hugo Aerts 1174 
(33,34), Alan Kirk (35), Mo Asif (35), John Butler (35), Rocco Bilanca (35), Nikos Kostoulas 1175 
(35), Mairead MacKenzie (36), Maggie Wilcox (36), Sara Busacca (37), Alan Dawson (37), 1176 
Mark R Lovett (37), Michael Shackcloth (38), Sarah Feeney (38), Julius Asante-Siaw (38), 1177 
John Gosney (39), Angela Leek (40), Nicola Totten (40), Jack Davies Hodgkinson (40), Rachael 1178 
Waddington (40), Jane Rogan (40), Katrina Moore (40), William Monteiro (41), Hilary 1179 
Marshall (41), Kevin G Blyth (42), Craig Dick (42), Andrew Kidd (42), Eric Lim (43), Paulo De 1180 
 36
Sousa (43), Simon Jordan (43), Alexandra Rice (43), Hilgardt Raubenheimer (43), Harshil 1181 
Bhayani (43), Morag Hamilton (43), Lyn Ambrose (43), Anand Devaraj (43), Hema Chavan 1182 
(43), Sofina Begum (43), Aleksander Mani (43), Daniel Kaniu (43), Mpho Malima (43), Sarah 1183 
Booth (43), Andrew G Nicholson (43), Nadia Fernandes (43), Jessica E  Wallen (43), Pratibha 1184 
Shah (43), Sarah Danson (44), Jonathan Bury (44), John Edwards (44), Jennifer Hill (44), Sue 1185 
Matthews (44), Yota Kitsanta (44), Jagan Rao (44), Sara Tenconi (44), Laura Socci (44), Kim 1186 
Suvarna (44), Faith Kibutu (44), Patricia Fisher (44), Robin Young (44), Joann Barker (44), 1187 
Fiona Taylor (44), Kirsty Lloyd (44), Teresa Light (45), Tracey Horey (45), Dionysis Papadatos-1188 
Pastos (45, 47), Peter Russell (45), Sara Lock (46), Kayleigh Gilbert (46), David Lawrence (47), 1189 
Martin Hayward (47), Nikolaos Panagiotopoulos (47), Robert George (47), Davide Patrini 1190 
(47), Mary Falzon (47), Elaine Borg (47), Reena Khiroya (47), Asia Ahmed (47), Magali Taylor 1191 
(47), Junaid Choudhary (47), Penny Shaw (47), Sam M Janes (47), Martin Forster (47), Tanya 1192 
Ahmad (47), Siow Ming Lee (47), Javier Herrero (47), Dawn Carnell (47), Ruheena Mendes 1193 
(47), Jeremy George (47), Neal Navani (47), Marco Scarci (47), Elisa Bertoja (47), Robert CM 1194 
Stephens (47), Emilie Martinoni Hoogenboom (47), James W Holding (47), Steve Bandula 1195 
(47), Babu Naidu (48), Gerald Langman (48), Andrew Robinson (48), Hollie Bancroft (48), 1196 
Amy Kerr (48), Salma Kadiri (48), Charlotte Ferris (48), Gary Middleton (48), Madava 1197 
Djearaman (48), Akshay Patel (48), Christian Ottensmeier (49), Serena Chee (49), Benjamin 1198 
Johnson (49), Aiman Alzetani (49), Emily Shaw (49), Jason Lester (50), Yvonne Summers (51), 1199 
Raffaele Califano (51), Paul Taylor (51), Rajesh Shah (51), Piotr Krysiak (51), Kendadai 1200 
Rammohan (51), Eustace Fontaine (51), Richard Booton (51), Matthew Evison (51), Stuart 1201 
Moss (51), Juliette Novasio (51), Leena Joseph (51), Paul Bishop (51), Anshuman Chaturvedi 1202 
(51), Helen Doran (51), Felice Granato (51), Vijay Joshi (51), Elaine Smith (51), Angeles 1203 
Montero (51) 1204 
 1205 
TRACERx consortium affiliations 1206 
(3) Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer 1207 
Institute, London, UK 1208 
(4) Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK 1209 
(5) Department of Medical Oncology, University College London Hospitals NHS Foundation 1210 
Trust, London, UK 1211 
(6) Department of Cellular Pathology, University College London, University College Hospital, 1212 
London, UK 1213 
(7) Translational Immune Oncology Group, Centre for Molecular Medicine, Royal Marsden 1214 
Hospital NHS Trust, London, UK 1215 
(8) Department of Pathology, GZA-ZNA-Ziekenhuizen, Antwerp, Belgium 1216 
(9) Division of Research, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, 1217 
Victoria, Australia 1218 
(10) MRC Toxicology Unit, Lancaster Road, University of Cambridge, Leicester, UK 1219 
 37
(11) Leicester Cancer Research Centre, University of Leicester, Leicester, UK 1220 
(12) Cancer Research UK & University College London Cancer Trials Centre, University College 1221 
London, London, UK 1222 
(13) Cancer Immunology Unit, University College London Cancer Institute, London, UK 1223 
(14) Cancer Genome Evolution Research Group, University College London Cancer Institute, 1224 
University College London, London, UK 1225 
(15) Glenfield Hospital, University Hospitals Leicester NHS Trust, Groby Road, Leicester, UK 1226 
(16) Cancer Research Centre, University of Leicester, Leicester, United Kingdom 1227 
(17) The Francis Crick Institute, London, United Kingdom 1228 
(18) University College London Cancer Institute, London, United Kingdom 1229 
(19) Aberdeen Royal Infirmary, Aberdeen, United Kingdom 1230 
(20) Ashford and St Peter's Hospitals NHS Foundation Trust 1231 
(21) Barnet & Chase Farm Hospitals, United Kingdom 1232 
(22) Barts Health NHS Trust 1233 
(23) Berlin Institute for Medical Systems Biology, Max Delbrueck Center for Molecular Medicine, 1234 
Berlin, Germany 1235 
(24) German Cancer Consortium (DKTK), partner site Berlin 1236 
(25) German Cancer Research Center (DKFZ), Heidelberg 1237 
(26) Cancer Research UK Manchester Institute, University of Manchester, Manchester, UK 1238 
(27) Cancer Research UK Lung Cancer Centre of Excellence, University of Manchester, 1239 
Manchester, UK 1240 
(28) Leicester University Hospitals, Leicester, United Kingdom 1241 
(29) Cardiff & Vale University Health Board, Cardiff, Wales 1242 
(30) Christie NHS Foundation Trust, Manchester, United Kingdom 1243 
(31) Danish Cancer Society Research Center, Copenhagen, Denmark 1244 
(32) Department of Physics of Complex Systems, ELTE Eötvös Loránd University, Budapest, 1245 
Hungary 1246 
(33) Departments of Radiation Oncology and Radiology, Dana Farber Cancer Institute, Brigham 1247 
and Women’s Hospital, Harvard Medical School, Boston, MA, USA 1248 
(34) Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands  1249 
(35) Golden Jubilee National Hospital 1250 
(36) Independent Cancer Patients Voice 1251 
(37) University of Leicester, Leicester, United Kingdom 1252 
 38
(38) Liverpool Heart and Chest Hospital NHS Foundation Trust 1253 
(39) Royal Liverpool University Hospital 1254 
(40) Manchester Cancer Research Centre Biobank, Manchester, United Kingdom 1255 
(41) National Institute for Health Research Leicester Respiratory Biomedical Research Unit, 1256 
Leicester, United Kingdom 1257 
(42) NHS Greater Glasgow and Clyde 1258 
(43) Royal Brompton and Harefield NHS Foundation Trust 1259 
(44) Sheffield Teaching Hospitals NHS Foundation Trust 1260 
(45) The Princess Alexandra Hospital NHS Trust 1261 
(46) The Whittington Hospital NHS Trust, London, United Kingdom 1262 
(47) University College London Hospitals, London, United Kingdom 1263 
(48) University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom 1264 
(49) University Hospital Southampton NHS Foundation Trust 1265 
(50) Velindre Cancer Centre, Cardiff, Wales 1266 
(51) Wythenshawe Hospital, Manchester University NHS Foundation Trust 1267 
(52) Division of Infection, Immunity and Respiratory Medicine, University of Manchester, 1268 
Manchester, UK 1269 
 1270 













